(Q34766538)

4 August 2017

1 reference

title

5-HT2C ligands: recent progress (English)

1 reference

4 August 2017

Nathaniel J T Monck

1

1 reference

4 August 2017

Guy A Kennett

series ordinal

2

1 reference

4 August 2017

publication date

1 January 2008

1 reference

Progress in medicinal chemistry

4 August 2017

published in

1 reference

4 August 2017

volume

46

1 reference

4 August 2017

page(s)

281-390

1 reference

History of serotonin and serotinin disorders

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

A review of central 5-HT receptors and their function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Anatomy of the serotonergic system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Differential effects of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-hydroxytryptamine(2C) receptor-mediated responses

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Pharmacological characterisation of human 5-HT2 receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Distribution of serotonin 2A, 2C and 3 receptor mRNA in spinal cord and medulla oblongata

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Expression of serotonin 5-HT2C receptors in GABAergic cells of the anterior raphe nuclei

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Regulation of serotonin-2C receptor G-protein coupling by RNA editing

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The potential use of selective 5-HT2C agonists in treating obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Monoamine receptors in the regulation of feeding behaviour and energy balance.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT(2C) receptor mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Evidence for a role of the 5-HT2C receptor in central lipopolysaccharide-, interleukin-1 beta-, and leptin-induced anorexia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin 2C receptor agonists and the behavioural satiety sequence in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2C receptor activation decreases appetite and body weight in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Oral administration of the 5-HT2Creceptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Thermogenic effect of YM348, a novel 5-HT2C-receptor agonist, in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effect of chronic m-CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Tolerance to anorectic drugs: pharmacological or artifactual

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Modulation of GABAA receptor function by G protein-coupled 5-HT2C receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Role of 5-HT in stress, anxiety, and depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Lack of central 5-hydroxytryptamine influence on the anticonflict activity of diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effect of 5-HT2C receptor antagonist RS 102221 on mouse behavior

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Genes and aggressiveness. Behavioral genetics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Ritanserin facilitates anxiety in a simulated public-speaking paradigm.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effects of fenfluramine on plasma HVA in OCD.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Compulsive behavior in the 5-HT2C receptor knockout mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin 2C receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin 5-HT(2C) receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Cocaine self-administration selectively abolishes LTD in the core of the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Catecholamine mapping within nucleus accumbens: differences in basal and amphetamine-stimulated efflux of norepinephrine and dopamine in shell and core

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Reward system and addiction: what dopamine does and doesn't do.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Modulation of dopamine release by striatal 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Functional and anatomical aspects of prefrontal pathology in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The MCPP challenge test in schizophrenia: hormonal and behavioral responses

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Current and novel approaches to the drug treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonergic and histaminergic mechanisms involved in intralipid drinking?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Evidence that imipramine activates 5-HT1C receptor function.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients. Initial experience with a serotonin agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

SSRI treatment decreases prolactin and hyperthermic responses to mCPP.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5HT1C receptor activation in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Moderate dieting causes 5-HT2C receptor supersensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The effects of a low tryptophan diet on brain 5 -HT metabolism and 5-HT-mediated neuroendocrine responses in the male rat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Increased 5-HT2C receptor responsiveness occurs on rearing rats in social isolation.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Effect of reserpine on behavioural responses to agonists at 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptor subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Agonist-induced functional desensitization of recombinant human 5-HT2 receptors expressed in CHO-K1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Newer treatment studies for bipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

An investigation of the role of 5-HT(2C) receptors in modifying ethanol self-administration behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin2C receptors (5-HT2C R) control expression of cocaine-induced conditioned hyperactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Sound-induced seizures in serotonin 5-HT2c receptor mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Global increases in seizure susceptibility in mice lacking 5-HT2C receptors: a behavioral analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The role of serotonin(2) receptors in mediating cocaine-induced convulsions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Studies on the role of 5-HT2C and 5-HT2B receptors in regulating generalised seizure threshold in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2 receptor subtypes: a family re-united?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Selective agents for serotonin2C (5-HT2C) receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Hallucinogens, serotonin and obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Indoline derivatives as 5-HT(2C) receptor agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Drug-induced phospholipidosis: issues and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Serotonin releasing agents. Neurochemical, therapeutic and adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Design and Synthesis of trans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro- 1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3 Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Studies towards the identification of a new generation of atypical antipsychotic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Development of an affinity ligand for purification of .alpha.2-adrenoceptors from human platelet membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Synthesis and resolution of the novel appetite suppressant 2-benzylmorpholine, a nonstimulant isomer of phenmetrazine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2807%2900006-9

7 January 2021

10.1016/S0079-6468(07)00006-9

Identifiers

DOI

1 reference

4 August 2017

1 reference